SCHEMBL6959042

SCHEMBL6959042

CC(C)(C)OCCOc1cccc(Br)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.59
CDK9 P50750 1/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK2 Q92630 1/20 0.38
NPY5R Q15761 1/20 0.36
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
GRM4 Q14833 3/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NUDT1 P36639 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
KDM4E B2RXH2 2/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
MCHR1 Q99705 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23364685 0.83 HTR7 (0.63) HTR7CDK9DYRK1ADYRK2HTR1A
SCHEMBL29932740 0.83 HTR7 (0.63) HTR7CDK9DYRK1ADYRK2HTR1A
SCHEMBL25028948 0.81 HTR7 (0.65) HTR7CDK9DYRK1ADYRK2HTR1A
SCHEMBL23355733 0.80 HTR7 (0.55) HTR7CDK9DYRK1ADYRK2NUDT1
SCHEMBL6743 0.79 HTR7 (0.67) HTR7CDK9DYRK1ADYRK2HTR1A
SCHEMBL6377587 0.78 HTR7 (0.61) HTR7CDK9DYRK1ADYRK2LMNA
SCHEMBL7285 0.77 HTR7 (0.65) HTR7CDK9DYRK1ADYRK2LMNA
SCHEMBL31637930 0.76 HTR7 (0.51) HTR7CDK9DYRK1ADYRK2CHRNB2
SCHEMBL31638152 0.76 HTR7 (0.48) HTR7CDK9DYRK1ADYRK2CHRNB2
SCHEMBL16637887 0.76 HTR7 (0.63) HTR7CDK9DYRK1ADYRK2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 HTR7 3967/4885CDK9 2460/4885DYRK1A 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.